Venmax Drugs & Pharmaceuticals (BOM:531015) Beta: -0.9972 (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531015 Venmax Drugs & Pharmaceuticals Ltd BOM:531015
33 GF Score
Price ₹17.89
! 3 Warning Signs
View Full Analysis

What is Venmax Drugs & Pharmaceuticals Beta?

Venmax Drugs & Pharmaceuticals BOM:531015 +1.88% 33 Beta is -0.9972 as of Jul. 30, 2026. GuruFocus rates BOM:531015 with a GF Score™ of 33/100. The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-30), Venmax Drugs & Pharmaceuticals's Beta is -0.9972.

Venmax Drugs & Pharmaceuticals  (BOM:531015) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Venmax Drugs & Pharmaceuticals Beta Related Terms

Venmax Drugs & Pharmaceuticals Beta Historical Data

* Premium members only.

The historical data trend for Venmax Drugs & Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Venmax Drugs & Pharmaceuticals Beta Chart

Venmax Drugs & Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -1.29 -0.99

Venmax Drugs & Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.29 -1.91 -2.03 -1.83 -0.99

BOM:531015 vs ZTS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Venmax Drugs & Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Venmax Drugs & Pharmaceuticals Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Venmax Drugs & Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where Venmax Drugs & Pharmaceuticals's Beta falls into.


BOM:531015
33GF Score
Venmax Drugs & Pharmaceuticals Ltd BOM:531015
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Venmax Drugs & Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.9972 mean?
Venmax Drugs & Pharmaceuticals (BOM:531015) has a Beta of -0.9972 as of Jul. 30, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Venmax Drugs & Pharmaceuticals and its competitors.
Is Venmax Drugs & Pharmaceuticals' Beta too high?
Venmax Drugs & Pharmaceuticals' current Beta is -0.9972. Overall, Venmax Drugs & Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Venmax Drugs & Pharmaceuticals' Beta compare to ZTS?
Venmax Drugs & Pharmaceuticals' Beta of -0.9972 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Venmax Drugs & Pharmaceuticals and its competitors. Venmax Drugs & Pharmaceuticals's current Beta is -0.9972. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venmax Drugs & Pharmaceuticals stock overvalued right now?
Venmax Drugs & Pharmaceuticals (BOM:531015) has a current Beta of -0.9972. The current Beta is -0.9972. Venmax Drugs & Pharmaceuticals' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Venmax Drugs & Pharmaceuticals (BOM:531015), the current Beta is -0.9972 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Venmax Drugs & Pharmaceuticals Business Description

Address Brig Sayeed Road, Sy.No.115, Hanumanji Colony, B, Bowenpally Picket, Hyderabad, TG, IND, 500051
Venmax Drugs & Pharmaceuticals Ltd is engaged in the manufacturing and sale of bulk drugs. The company is engaged in the business of IT & ITES services.
33GF Score

Get the complete analysis for BOM:531015

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹17.89
Price